TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
出版年份 2021 全文链接
标题
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
作者
关键词
-
出版物
Frontiers in Immunology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-07-22
DOI
10.3389/fimmu.2021.699895
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
- (2021) Julianne D. Twomey et al. AAPS Journal
- TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma
- (2021) Zhouhong Ge et al. Cellular and Molecular Gastroenterology and Hepatology
- TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer
- (2020) Danhua Xu et al. IMMUNOBIOLOGY
- Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma
- (2020) Ailin Lepletier et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice
- (2020) David Kung-Chun Chiu et al. GASTROENTEROLOGY
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
- (2020) Delvys Rodriguez-Abreu et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming genetically-based resistance mechanisms to PD-1 blockade
- (2020) Davis Y. Torrejon et al. Cancer Discovery
- CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
- (2020) Hyung-seung Jin et al. Cancer Immunology Research
- Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS
- (2020) Liliana E. Lucca et al. Neurology-Neuroimmunology & Neuroinflammation
- TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma
- (2020) Zhi-Zhang Yang et al. CLINICAL CANCER RESEARCH
- Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma
- (2020) Ester Lozano et al. CLINICAL CANCER RESEARCH
- IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
- (2020) Joe-Marc Chauvin et al. CLINICAL CANCER RESEARCH
- Transcriptome profiling identifies TIGIT as a marker of T cell exhaustion in liver cancer
- (2020) Dmitrij Ostroumov et al. HEPATOLOGY
- Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
- (2020) Adi Reches et al. Journal for ImmunoTherapy of Cancer
- 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
- (2020) M-J. Ahn et al. ANNALS OF ONCOLOGY
- 1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
- (2020) J. Niu et al. ANNALS OF ONCOLOGY
- Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy
- (2020) Marianne Weulersse et al. IMMUNITY
- PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
- (2020) Catherine L. Tan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
- (2019) Fernando Souza-Fonseca-Guimaraes et al. TRENDS IN IMMUNOLOGY
- PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function
- (2019) Sarah Whelan et al. Cancer Immunology Research
- Mouse PVRIG Has CD8+ T Cell–Specific Coinhibitory Functions and Dampens Antitumor Immunity
- (2019) Benjamin Murter et al. Cancer Immunology Research
- TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma
- (2019) Sarah E Josefsson et al. Cancer Immunology Research
- DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
- (2019) Beatriz Sanchez-Correa et al. Cancers
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
- (2019) Lei Wu et al. Cancer Immunology Research
- PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma
- (2019) Xiaoli Liu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
- (2019) Jiaqiang Ma et al. Journal for ImmunoTherapy of Cancer
- TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma
- (2018) Camille Guillerey et al. BLOOD
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
- (2018) Jan P. Böttcher et al. CELL
- Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
- (2018) Yinghao Zhao et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
- (2018) Xian-Yang Li et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity
- (2018) Karen O. Dixon et al. JOURNAL OF IMMUNOLOGY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
- (2018) Alice L. Hung et al. OncoImmunology
- Emerging strategies for combination checkpoint modulators in cancer immunotherapy
- (2018) Aleksandra Popovic et al. JOURNAL OF CLINICAL INVESTIGATION
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Human CD96 correlates to NK cell exhaustion and predicts the prognosis of human hepatocellular carcinoma
- (2018) Haoyu Sun et al. HEPATOLOGY
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- (2017) Bert H. O’Neil et al. PLoS One
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
- (2016) Y. Kong et al. CLINICAL CANCER RESEARCH
- Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
- (2016) Marco De Simone et al. IMMUNITY
- Identification of CD112R as a novel checkpoint for human T cells
- (2016) Yuwen Zhu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
- (2016) Takashi Inozume et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- “Natural Regulators”: NK Cells as Modulators of T Cell Immunity
- (2016) Iona S. Schuster et al. Frontiers in Immunology
- Recognition and Regulation of T Cells by NK Cells
- (2016) Katharina Pallmer et al. Frontiers in Immunology
- TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals
- (2015) Feng Wang et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
- (2015) Chamutal Gur et al. IMMUNITY
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226
- (2015) Christopher A. Fuhrman et al. JOURNAL OF IMMUNOLOGY
- PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+T Cells
- (2015) Hyo Jin Park et al. JOURNAL OF IMMUNOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
- (2015) Valentina Bevelacqua et al. Oncotarget
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit
- (2014) Kristen E. Pauken et al. CANCER CELL
- Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
- (2014) Nicole Joller et al. IMMUNITY
- T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling
- (2014) Man Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer
- (2014) M. C. B. Tan et al. JOURNAL OF IMMUNOLOGY
- Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
- (2013) Eric O. Long et al. Annual Review of Immunology
- CFL1 and Arp3 are Biomarkers for Metastasis and Poor Prognosis of Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas of Gallbladder
- (2013) Zhu-Lin Yang et al. CANCER INVESTIGATION
- Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
- (2012) S Liu et al. CELL DEATH AND DIFFERENTIATION
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Vstm3 is a member of the CD28 family and an important modulator of T-cell function
- (2011) Steven D. Levin et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients
- (2011) Beatriz Sanchez-Correa et al. IMMUNOLOGY AND CELL BIOLOGY
- Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
- (2011) N. Joller et al. JOURNAL OF IMMUNOLOGY
- Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma
- (2010) Reiko Nakai et al. CANCER SCIENCE
- Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines
- (2009) Javier G. Casado et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
- (2009) Kent S. Boles et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV
- (2009) Debora Franceschini et al. JOURNAL OF CLINICAL INVESTIGATION
- Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
- (2009) M. Carlsten et al. JOURNAL OF IMMUNOLOGY
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search